ICU Medical (NASDAQ:ICUI) Given "Hold" Rating at Needham & Company LLC

ICU Medical (NASDAQ:ICUI - Get Free Report)'s stock had its "hold" rating reaffirmed by equities research analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports.

ICUI has been the topic of a number of other reports. StockNews.com raised ICU Medical from a "hold" rating to a "buy" rating in a report on Thursday, September 12th. Raymond James upped their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a research note on Thursday, September 12th. Finally, KeyCorp boosted their price objective on shares of ICU Medical from $136.00 to $147.00 and gave the company an "overweight" rating in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $149.00.

ICU Medical Stock Down 2.8 %

Shares of ICUI traded down $5.12 during trading hours on Thursday, hitting $177.03. The company had a trading volume of 204,494 shares, compared to its average volume of 283,238. The stock has a market capitalization of $4.31 billion, a price-to-earnings ratio of -72.21 and a beta of 0.66. The firm has a fifty day moving average price of $163.30 and a 200-day moving average price of $128.52. ICU Medical has a 52-week low of $78.28 and a 52-week high of $188.53. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The firm had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. During the same quarter in the prior year, the firm posted $1.58 earnings per share. The business's revenue was up 8.6% on a year-over-year basis. On average, equities research analysts forecast that ICU Medical will post 3.76 EPS for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,320,691.72. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CEO Vivek Jain sold 12,000 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the sale, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,552 shares of company stock worth $6,679,322 in the last three months. 6.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of ICU Medical by 14.8% during the fourth quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier's stock worth $243,438,000 after acquiring an additional 315,103 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in shares of ICU Medical by 109.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier's stock valued at $29,882,000 after purchasing an additional 145,485 shares during the last quarter. Mesirow Institutional Investment Management Inc. purchased a new position in shares of ICU Medical during the first quarter valued at about $15,425,000. Victory Capital Management Inc. increased its holdings in shares of ICU Medical by 2,966.3% in the second quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier's stock worth $16,844,000 after purchasing an additional 137,222 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of ICU Medical by 327.8% in the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier's stock worth $16,158,000 after buying an additional 104,264 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.